Crestline Management LP Has $87.85 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Crestline Management LP cut its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,310,732 shares of the company's stock after selling 150,000 shares during the quarter. Denali Therapeutics comprises 2.9% of Crestline Management LP's holdings, making the stock its 3rd biggest position. Crestline Management LP owned approximately 3.00% of Denali Therapeutics worth $87,853,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of Denali Therapeutics during the fourth quarter valued at approximately $532,000. Proficio Capital Partners LLC acquired a new position in Denali Therapeutics during the 4th quarter worth $514,000. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock worth $6,857,000 after purchasing an additional 14,324 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after purchasing an additional 149,939 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Denali Therapeutics by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock worth $244,993,000 after purchasing an additional 843,996 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Trading Down 0.3 %

Shares of NASDAQ:DNLI traded down $0.04 during midday trading on Friday, hitting $14.39. The company had a trading volume of 1,367,985 shares, compared to its average volume of 1,092,248. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The firm has a fifty day simple moving average of $14.27 and a 200 day simple moving average of $20.04. The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -5.21 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the business posted ($0.68) earnings per share. Equities analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DNLI shares. HC Wainwright reduced their price objective on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday. B. Riley restated a "buy" rating and set a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Robert W. Baird decreased their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday. Oppenheimer lowered their price target on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group cut their target price on Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.